Cargando…
Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that inhibit IgE binding to its high- and low-affinit...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236630/ https://www.ncbi.nlm.nih.gov/pubmed/30400762 http://dx.doi.org/10.1177/1753466618810192 |